莫林黄化合物与白蛋白的相互作用及其纳米粒子结合:一种有效的抗氧化剂载体,用于营养药
Guillermo Montero1, Víctor Guarnizo-Herrero2, Catalina Sandoval-Altamirano3
1Facultad de Ciencias, Universidad San Sebastián, Santiago 7510157, Chile.
Antioxidants (Basel, Switzerland)
|July 29, 2025
概括
牛血清专纳米颗粒通过增强其溶解性和稳定性,有效地提供一种强有力的抗氧化剂 - - 摩林. 这一突破改善了多化合物的口服和功能性食品应用.
科学领域:
- 生物化学 生物化学
- 材料科学 材料科学 材料科学
- 食品科学 食品科学 食品科学
背景情况:
- 莫林是一种天然的黄类化合物,具有显著的抗氧化特性,但具有不良的溶解性和低生物可用性,限制了其治疗和营养药物的使用.
- 开发有效的交付系统至关重要,以克服这些局限性,并充分利用海洋的潜力.
研究的目的:
- 为了研究莫林和牛血清白蛋白 (BSA) 之间的相互作用.
- 开发基于BSA的纳米粒子,以增强Morin的交付.
- 为了评估在各种条件下,morin装载的BSA纳米颗粒的稳定性和释放特性.
主要方法:
- 光谱法被用来研究morin-BSA复合体的形成和结合动力学.
- 使用解溶方法制备了BSA纳米颗粒.
- 评估了食品矩阵中的封装效率,单分散性和稳定性.
- 实验室释放研究是在模拟的肠液中进行的.
主要成果:
- 一个稳定的 1:1 摩林-BSA 复合物,通过疏水相互作用形成,结合常数为 1.87 × 10^5 L·mol^-1.
- BSA封装改善了莫林对抗氧化应激的光稳定性.
- BSA纳米粒子实现了高单分散性和高达26%的莫林封装效率.
- 在模拟的肠液中观察到受控的莫林释放,在基于牛奶的食物矩阵中具有良好的体稳定性.
结论:
- BSA-莫林纳米颗粒代表了一种可行的系统,可以提高莫林的口服生物可用性和稳定性.
- 这些纳米颗粒有望被纳入功能性食品中,改善抗氧化剂的输送.
- 这项研究强调了基于蛋白质的纳米颗粒在提供难以溶解的多化合物的潜力.
相关概念视频
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
280
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
280
01:29Drug Distribution: Plasma Protein Binding
6.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.7K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
260
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
260
01:09Hepatic Drug Clearance: Effect of Protein Binding
285
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
285
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
277
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
277